InfuSystems (INFU) vs TriSalus Life Sciences (TLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
InfuSystems (INFU) has outperformed TriSalus Life Sciences (TLSI) over the past year, gaining 36.6% versus a loss of 14.8%. Over five years, INFU leads with a +4.2% price change compared with -58.3% for TLSI. InfuSystems is the larger company by market cap ($268.7 million vs $254.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INFU | TLSI |
|---|---|---|
| Share price | $13.49 | $4.13 |
| Market cap | $268.68M | $254.30M |
| 1-day change | +0.60% | 0.00% |
| YTD return | +49.50% | -40.83% |
| 1-year return | +36.56% | -14.85% |
| 5-year return | +4.20% | -58.28% |
| P/E ratio (TTM) | 33.73 | — |
| Forward P/E | 25.94 | — |
| EPS (TTM) | $0.40 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.85 | $7.95 |
| 52-week low | $7.29 | $2.20 |
| Distance from 52-week high | -2.60% | -48.05% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +24.76% | +151.82% |
| Average volume | 140.07K | 275.38K |
| Shares outstanding | 19.92M | 61.57M |
| Employees | 461 | 102 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INFU has outperformed TLSI by 51.4 percentage points over the past year.
About InfuSystems
INFU stock →InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions.
Health Care · Medical/Dental Instruments · 461 employees
About TriSalus Life Sciences
TLSI stock →TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
Health Care · Medical Specialities · 102 employees
INFU vs TLSI FAQ
Which is bigger, InfuSystems or TriSalus Life Sciences?
InfuSystems (INFU) is larger, with a market capitalization of $268.68M compared with $254.30M for TriSalus Life Sciences (TLSI).
Which stock has performed better over the past year, INFU or TLSI?
INFU returned +36.56% over the past 12 months, compared with -14.85% for TLSI (price return, excluding dividends). Past performance does not predict future results.
Are InfuSystems and TriSalus Life Sciences in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for InfuSystems and Medical Specialities for TriSalus Life Sciences.